Not long ago, diogenes posted this:
Apparently there are few longterm ill effects from taking T3 only or T3/T4 combination
Today I noticed a new paper from Dundee saying something similar:
Clin Endocrinol (Oxf). 2016 Mar 4. doi: 10.1111/cen.13052. [Epub ahead of print]
Liothyronine use in a 17 year observational population-based study - The tears study.
Leese GP1, Soto-Pedre E2, Donnelly LA2.
1Department of Endocrinology and Diabetes, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
2Division of Cardiovascular & Diabetes Medicine, School Of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
To look at adverse outcomes for patients on liothyronine compared to l-thyroxine. Some trials have examined the relative merits of liothyronine but none have looked at adverse outcomes in large numbers
An observational study of all patients prescribed thyroid hormone replacement in Tayside Scotland (population 400,000) from 1997 to 2014.
A study group of patients having ever used liothyronine (n=400) was compared to those who had only used l-thyroxine (n=33,955). All patients were followed up until end-point, death or leaving Tayside.
Mortality rates and admissions with cardiovascular disease, atrial fibrillation, fractures, breast cancer and mental diseases were compared. Incident use of bisphosphonates, statins, anti-depressants and anti-psychotics was compared.
Compared to patients only taking l-thyroxine, those using liothyronine had no increased risk of cardiovascular disease (hazard ratio (HR) 1.04; 95% CI 0.70-1.54), atrial fibrillation (HR 0.91: 0.47-1.75), or fractures (HR 0.79: 0.49-1.27) after adjusting for age. There was no difference in the number of prescriptions for bisphosphonates or statins. There was an increased risk of new prescriptions for anti-psychotic medication (HR 2.26: 1.64-3.11 p<0.0001) which was proportional to the number of liothyronine prescriptions. There was a non-significant trend towards an increase in breast cancer and new use of anti-depressant medications. During follow-up, median TSH was higher for patients on l-thyroxine alone (2.08 vs 1.07 mU/L; P<0.001).
For patients taking long-term liothyronine we did not identify any additional risk of atrial fibrillation, cardiovascular disease or fractures. There was an increased incident use of antipsychotic medication during follow up. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
hypothyroid; liothyronine; safety; thyroid; thyroxine
PMID: 26940864 [PubMed - as supplied by publisher]
Have to say, how on earth did it come to pass that they had enough patients on T3 at all to do a study? Current situation seems to make the possibility of a follow-up or follow-on from this impossible in the UK. There won't be anyone prescribed T3. Unless they actually use patients who are self-medicating.
Added when I found it:
The TEARS study